Disease on EC 1.1.1.284 - S-(hydroxymethyl)glutathione dehydrogenase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy.
Amyotrophic Lateral Sclerosis
nNOS/GSNOR interaction contributes to skeletal muscle differentiation and homeostasis.
S-Nitrosoglutathione Reductase Plays Opposite Roles in SH-SY5Y Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.
Anemia
Priming of hypoxia-inducible factor by neuronal nitric oxide synthase is essential for adaptive responses to severe anemia.
Anemia, Hypochromic
Overexpression of S-nitrosoglutathione reductase alleviated iron-deficiency stress by regulating iron distribution and redox homeostasis.
Asthma
A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma.
Discovery of potent and novel S-nitrosoglutathione reductase inhibitors devoid of cytochrome P450 activities.
Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.
Exhaled breath condensate formate after inhaled allergen provocation in atopic asthmatics in vivo.
Genetic variants of GSNOR and ADRB2 influence response to albuterol in African-American children with severe asthma.
Genetic variation in S-nitrosoglutathione reductase (GSNOR) and childhood asthma.
GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol.
Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice.
Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting S-Nitrosoglutathione Reductase.
Mechanistic considerations for formaldehyde-induced bronchoconstriction involving S-nitrosoglutathione reductase.
Pharmacologic inhibition of S-nitrosoglutathione reductase protects against experimental asthma in BALB/c mice through attenuation of both bronchoconstriction and inflammation.
Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity.
Protection from experimental asthma by an endogenous bronchodilator.
Proteomic Characterization of the Cellular Response to Nitrosative Stress Mediated by S-Nitrosoglutathione Reductase Inhibition.
S-Nitrosoglutathione Reductase -- An Important Regulator in Human Asthma.
S-Nitrosoglutathione reductase in human lung cancer.
S-nitrosoglutathione Supplementation To Ovalbumin Sensitized and Challenged Mice Ameliorates Methacholine-Induced Bronchoconstriction.
Structure-activity relationship of pyrrole based S-nitrosoglutathione reductase inhibitors: Carboxamide modification.
The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy.
Atherosclerosis
GSNOR modulates hyperhomocysteinemia-induced T cell activation and atherosclerosis by switching Akt S-nitrosylation to phosphorylation.
Brain Injuries
Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase.
Breast Neoplasms
A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells.
Altered S-nitrosothiol homeostasis provides a survival advantage to breast cancer cells in HER2 tumors and reduces their sensitivity to trastuzumab.
Antitumor immune responses mediated by adenoviral GDEPT using nitroreductase/CB1954 is enhanced by high-level coexpression of heat shock protein 70.
Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Bronchial Hyperreactivity
Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.
Carcinogenesis
Cell-free whey from milk fermented with Bifidobacterium breve C50 used to modify the colonic microflora of healthy subjects.
Effect of chronic ingestion of a fermented dairy product containing Lactobacillus acidophilus and Bifidobacterium bifidum on metabolic activities of the colonic flora in humans.
Inhibition of Grb2-mediated activation of MAPK signal transduction suppresses NOR1/CB1954-induced cytotoxicity in the HepG2 cell line.
Metabolic reduction of novel 3,4-dichloro-5-nitrofurans in Salmonella typhimurium.
Proteomic analysis of the role of S-nitrosoglutathione reductase in lipopolysaccharide-challenged mice.
Tumor Suppressor Roles of the Denitrosylase GSNOR.
Carcinoma
A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT.
A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells.
Cytotoxicity and activation of CB1954 in a human tumour cell line.
Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase.
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2).
Carcinoma, Hepatocellular
Comparative gastrointestinal enzyme activity and activation of the promutagen 2,6-dinitrotoluene in male CD-1 mice and male Fischer 344 rats.
Proteomic analysis of the role of S-nitrosoglutathione reductase in lipopolysaccharide-challenged mice.
S-nitrosylation of the Mitochondrial Chaperone TRAP1 Sensitizes Hepatocellular Carcinoma Cells to Inhibitors of Succinate Dehydrogenase.
Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine.
Cardiovascular Diseases
Kinetic and cellular characterization of novel inhibitors of S-nitrosoglutathione reductase.
Chagas Disease
Putative role of the aldo-keto reductase from Trypanosoma cruzi (TcAKR) in benznidazole metabolism.
Choriocarcinoma
Cytotoxicity and activation of CB1954 in a human tumour cell line.
Colonic Neoplasms
Comparison of four microbial enzymes in Clostridia and Bacteroides isolated from human feces.
Effect of dietary fiber on colonic bacterial enzymes and bile acids in relation to colon cancer.
Influence of diet and age on fecal bacterial enzymes.
Late Expression of Nitroreductase in an Oncolytic Adenovirus Sensitizes Colon Cancer Cells to the Prodrug CB1954.
Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
Reduction of beta-glucuronidase and nitroreductase activity by yoghurt in a murine colon cancer model.
Colorectal Neoplasms
Galacto-oligosaccharides and Colorectal Cancer: Feeding our Intestinal Probiome.
Coronary Artery Disease
GSNOR modulates hyperhomocysteinemia-induced T cell activation and atherosclerosis by switching Akt S-nitrosylation to phosphorylation.
Cystic Fibrosis
Augmentation of CFTR maturation by S-nitrosoglutathione reductase.
Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice.
Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.
The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy.
Demyelinating Diseases
A Drug-Inducible Transgenic Zebrafish Model for Myelinating Glial Cell Ablation.
Encephalomyelitis
S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis.
Gastrointestinal Diseases
[Frequency of Helicobacter pylori nitroreductase RdxA mutations for metronidazole activation in a population in the Cauca Department, Colombia].
Giardiasis
Introducing nitazoxanide as a promising alternative treatment for symptomatic to metronidazole-resistant giardiasis in clinical isolates.
Glioblastoma
Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors.
Glioma
Anomalous patterns of nitroimidazole binding adjacent to necrosis in human glioma xenografts: possible role of decreased oxygen consumption.
Healthcare-Associated Pneumonia
Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice.
Heart Arrest
Improvement in Outcomes After Cardiac Arrest and Resuscitation by Inhibition of S-Nitrosoglutathione Reductase.
Heart Failure
Proteomic Characterization of the Cellular Response to Nitrosative Stress Mediated by S-Nitrosoglutathione Reductase Inhibition.
Herpes Simplex
A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells.
Adenovirus-mediated hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-activating genes in vitro and in vivo.
Advances in Imaging Gene-Directed Enzyme Prodrug Therapy.
Bystander or no bystander for gene directed enzyme prodrug therapy.
Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Current progress in suicide gene therapy for cancer.
Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Prodrugs in genetic chemoradiotherapy.
Theranostic Imaging of Cancer Gene Therapy.
Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro.
Herpes Zoster
A transgenic zebrafish model of targeted oocyte ablation and de novo oogenesis.
Nitroreductase-mediated Gonadal Dysgenesis for Infertility Control of Genetically Modified Zebrafish.
Hypertension
Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo.
Hypertension, Pulmonary
Increased Nitrosoglutathione Reductase Activity in Hypoxic Pulmonary Hypertension in Mice.
Hypogonadism
S-Nitrosoglutathione Reductase (GSNOR) Deficiency Results in Secondary Hypogonadism.
Infections
Effects of metronidazole on proopiomelanocortin a gene expression in zebrafish.
Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.
Identification of a Novel Inhibitor of HRV Replication and Inflammation in Airway Epithelial Cells.
Immunodetection of S-Nitrosoglutathione Reductase Protein in Plant Samples.
Increased susceptibility to Klebsiella pneumonia and mortality in GSNOR-deficient mice.
Involvement of S-nitrosothiols modulation by S-nitrosoglutathione reductase in defence responses of lettuce and wild Lactuca spp. to biotrophic mildews.
S-Nitrosoglutathione Reductase Deficiency Confers Improved Survival and Neurological Outcome in Experimental Cerebral Malaria.
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Infertility, Male
Inducible Male Infertility by Targeted Cell Ablation in Zebrafish Testis.
Inflammatory Bowel Diseases
Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting S-Nitrosoglutathione Reductase.
Leishmaniasis
An Essential Type I Nitroreductase from Leishmania major Can Be Used to Activate Leishmanicidal Prodrugs.
Leishmaniasis, Visceral
Assessing the essentiality of Leishmania donovani nitroreductase and its role in nitro drug activation.
Liver Neoplasms
Inhibition of Grb2-mediated activation of MAPK signal transduction suppresses NOR1/CB1954-induced cytotoxicity in the HepG2 cell line.
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
Lung Diseases
A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma.
ADH IB expression, but not ADH III, is decreased in human lung cancer.
Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
Lung Diseases, Interstitial
The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy.
Lung Neoplasms
ADH IB expression, but not ADH III, is decreased in human lung cancer.
S-Nitrosoglutathione reductase in human lung cancer.
Lymphoma
Endogenous xenobiotic enzyme levels in mammalian cells.
The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Malaria
S-Nitrosoglutathione Reductase Deficiency Confers Improved Survival and Neurological Outcome in Experimental Cerebral Malaria.
Malaria, Cerebral
S-Nitrosoglutathione Reductase Deficiency Confers Improved Survival and Neurological Outcome in Experimental Cerebral Malaria.
Muscular Atrophy
nNOS/GSNOR interaction contributes to skeletal muscle differentiation and homeostasis.
Muscular Dystrophies
nNOS/GSNOR interaction contributes to skeletal muscle differentiation and homeostasis.
Myocardial Infarction
Endogenous S-nitrosothiols protect against myocardial injury.
S-Nitrosoglutathione Reductase Deficiency Enhances the Proliferative Expansion of Adult Heart Progenitors and Myocytes Post Myocardial Infarction.
Nasopharyngeal Carcinoma
Inhibition of Grb2-mediated activation of MAPK signal transduction suppresses NOR1/CB1954-induced cytotoxicity in the HepG2 cell line.
Overexpression of oxidored-nitro domain containing protein 1 inhibits human nasopharyngeal carcinoma and cervical cancer cell proliferation and induces apoptosis: Involvement of mitochondrial apoptotic pathways.
Preparation of polyclonal antibody specific for NOR1 and detection of its expression pattern in human tissues and nasopharyngeal carcinoma.
Neoplasms
A coelenterazine-type bioluminescent probe for nitroreductase imaging.
A highly sensitive chemiluminescent probe for detecting nitroreductase and imaging in living animal.
A mammalianized synthetic nitroreductase gene for high-level expression.
A new fluorescent probe with a large turn-on signal for imaging nitroreductase in tumor cells and tissues by two-photon microscopy.
A new prodrug-derived ratiometric fluorescent probe for hypoxia: high selectivity of nitroreductase and imaging in tumor cell.
A new tetraphenylethylene derived-fluorescence probe for nitroreductase detection and hypoxic tumor cell imaging.
A nitroreductase and acidity detecting dual functional ratiometric fluorescent probe for selectively imaging tumor cells.
A novel off-on fluorescent probe for sensitive imaging of mitochondria-specific nitroreductase activity in living tumor cells.
A Probe for the Detection of Hypoxic Cancer Cells.
A rapid response "Turn-On" fluorescent probe for nitroreductase detection and its application in hypoxic tumor cell imaging.
A sensitive and fast responsive fluorescent probe for imaging hypoxic tumors.
An unusually cold active nitroreductase for prodrug activations.
Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment.
Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Bystander cell killing spreading from endothelial to tumor cells in a three-dimensional multicellular nodule model after Escherichia coli nitroreductase gene delivery.
CB 1954: from the Walker tumor to NQO2 and VDEPT.
Colloidal gold modified with a genetically engineered nitroreductase: toward a novel enzyme delivery system for cancer prodrug therapy.
Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.
Combined antitumor activity of the nitroreductase/CB1954 suicide gene system and ?-rays in HeLa cells in vitro.
Comparative gastrointestinal enzyme activity and activation of the promutagen 2,6-dinitrotoluene in male CD-1 mice and male Fischer 344 rats.
Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme.
Delivery of the bacterial nitroreductase gene into endothelial cells prolongs the survival of tumour-bearing mice by bystander mechanisms.
Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
Dual-therapeutic reporter genes fusion for enhanced cancer gene therapy and imaging.
Efficient Two-Photon Fluorescent Probe for Nitroreductase Detection and Hypoxia Imaging in Tumor Cells and Tissues.
Endoplasmic reticulum-targeted two-photon turn-on fluorescent probe for nitroreductase in tumor cells and tissues.
Engineering a Multifunctional Nitroreductase for Improved Activation of Prodrugs and PET Probes for Cancer Gene Therapy.
Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors.
Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954.
Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.
High selectivity imaging of nitroreductase using a near-infrared fluorescence probe in hypoxic tumor.
Hypoxia imaging in cells and tumor tissues using a highly selective fluorescent nitroreductase probe.
Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells.
Hypoxia-triggered single molecule probe for high-contrast NIR II/PA tumor imaging and robust photothermal therapy.
Immunotherapy and gene therapy.
Increased Hepatocarcinogenesis from GSNOR Deficiency in mice is Prevented by Pharmacological Inhibition of iNOS.
Inhibition of NF-kappaB enhances the cytotoxicity of virus-directed enzyme prodrug therapy and oncolytic adenovirus cancer gene therapy.
Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
Mitochondrial Nitroreductase Activity Enables Selective Imaging and Therapeutic Targeting.
Multifunctional Probe Based on Cationic Conjugated Polymers for Nitroreductase-Related Analysis: Sensing, Hypoxia Diagnosis, and Imaging.
Naphthalimides in fluorescent imaging of tumor hypoxia - An up-to-date review.
Nitroreductase Detection and Hypoxic Tumor Cell Imaging by a Designed Sensitive and Selective Fluorescent Probe, 7-[(5-Nitrofuran-2-yl)methoxy]-3H-phenoxazin-3-one.
Nitroreductase gene-directed enzyme prodrug therapy: insights and advances toward clinical utility.
Nitroreductase-Activatable Theranostic Molecules with High PDT Efficiency under Mild Hypoxia Based on a TADF Fluorescein Derivative.
Nitroreductase-activated nitric oxide (NO) prodrugs.
Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity.
Overexpression of oxidored-nitro domain containing protein 1 inhibits human nasopharyngeal carcinoma and cervical cancer cell proliferation and induces apoptosis: Involvement of mitochondrial apoptotic pathways.
Oxygen and nitroreductase-dependent binding of AF-2 in spheroids and murine tumors.
Prodrugs For Nitroreductase Based Cancer Therapy- 1 Metabolite Profile, Cell Cytotoxicity and Molecular Modeling Interactions of Nitro Benzamides with Ssap-NtrB.
PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells.
Real-Time Bioluminescence Imaging of Nitroreductase in Mouse Model.
S-nitrosoglutathione reductase (GSNOR) deficiency-induced S-nitrosylation results in neuromuscular dysfunction.
Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase.
Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase.
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.
Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.
Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine.
Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954.
Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954.
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
The Flavin Reductase MsuE Is a Novel Nitroreductase that Can Efficiently Activate Two Promising Next-Generation Prodrugs for Gene-Directed Enzyme Prodrug Therapy.
The role of S-nitrosoglutathione reductase (GSNOR) in human disease and therapy.
Theranostic Imaging of Cancer Gene Therapy.
Tumor Suppressor Roles of the Denitrosylase GSNOR.
Two-photon fluorescent probe for detection of nitroreductase and hypoxia-specific microenvironment of cancer stem cell.
Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging.
Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer.
[Hypoxia in malignant tumors the target for clostridial therapeutic gene strategies]
Neuralgia
S-nitrosoglutathione reductase (GSNOR) deficiency-induced S-nitrosylation results in neuromuscular dysfunction.
Obstetric Labor, Premature
S-Nitrosoglutathione Reductase Underlies the Dysfunctional Relaxation to Nitric Oxide in Preterm Labor.
Ovarian Neoplasms
Sensitisation of human ovarian cancer cells to killing by the prodrug CB1954 following retroviral or adenoviral transfer of the E. coli nitroreductase gene.
Pancreatic Neoplasms
Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with pancreatic cancer.
Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.
Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954.
Pancreatitis
The Alcohol Dehydrogenase Isoenzyme as a Potential Marker of Pancreatitis.
Pancreatitis, Chronic
The Alcohol Dehydrogenase Isoenzyme as a Potential Marker of Pancreatitis.
Parkinson Disease
S-Nitrosoglutathione Reductase Plays Opposite Roles in SH-SY5Y Models of Parkinson's Disease and Amyotrophic Lateral Sclerosis.
Pneumonia
Discovery of s-nitrosoglutathione reductase inhibitors: potential agents for the treatment of asthma and other inflammatory diseases.
S-nitrosoglutathione reductase inhibition regulates allergen-induced lung inflammation and airway hyperreactivity.
Pouchitis
Azoreductase and nitroreductase activity of bacteria in feces from patients with an ileal reservoir.
Pre-Eclampsia
Pre-eclampsia: the Potential of GSNO Reductase Inhibitors.
Prostatic Neoplasms
A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase with CB1984.
Antivector and Tumor Immune Responses Following Adenovirus-Directed Enzyme Prodrug Therapy for the Treatment of Prostate Cancer.
Combining gene and immunotherapy for prostate cancer.
Corrigendum to "A Phase I/II Clinical Trial in Localized Prostate Cancer of an Adenovirus Expressing Nitroreductase With CB1984".
Pulmonary Disease, Chronic Obstructive
Discovery of 5-(2-chloro-4'-(1H-imidazol-1-yl)-[1,1'-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD.
Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting S-Nitrosoglutathione Reductase.
Reperfusion Injury
S-Nitrosoglutathione Reductase Is Essential for Protecting the Female Heart From Ischemia-Reperfusion Injury.
Respiratory Insufficiency
S-nitrosoglutathione Supplementation To Ovalbumin Sensitized and Challenged Mice Ameliorates Methacholine-Induced Bronchoconstriction.
s-(hydroxymethyl)glutathione dehydrogenase deficiency
Arabidopsis CaM1 and CaM4 Promote Nitric Oxide Production and Salt Resistance by Inhibiting S-Nitrosoglutathione Reductase via Direct Binding.
GSNOR Deficiency Enhances In Situ Skeletal Muscle Strength, Fatigue Resistance, and RyR1 S-Nitrosylation Without Impacting Mitochondrial Content and Activity.
Increased Hepatocarcinogenesis from GSNOR Deficiency in mice is Prevented by Pharmacological Inhibition of iNOS.
Lymphocyte Development Requires S-nitrosoglutathione Reductase.
Nitroarene reduction and generation of free radicals by cell-free extracts of wild-type, and nitroreductase-deficient and -enriched Salmonella typhimurium strains used in the umu gene induction assay.
Proteomic analysis of the role of S-nitrosoglutathione reductase in lipopolysaccharide-challenged mice.
Regulation of DNA repair by S-nitrosylation.
Relative refractoriness of guinea pigs to carcinogenesis by 5-nitrofurans.
S-nitrosoglutathione reductase (GSNOR) deficiency-induced S-nitrosylation results in neuromuscular dysfunction.
S-Nitrosoglutathione Reductase Deficiency Confers Improved Survival and Neurological Outcome in Experimental Cerebral Malaria.
S-Nitrosoglutathione Reductase Deficiency Enhances the Proliferative Expansion of Adult Heart Progenitors and Myocytes Post Myocardial Infarction.
S-nitrosoglutathione reductase deficiency increases mutagenesis from alkylation in mouse liver.
S-nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis.
S-nitrosylation of the Mitochondrial Chaperone TRAP1 Sensitizes Hepatocellular Carcinoma Cells to Inhibitors of Succinate Dehydrogenase.
Targeted deletion of GSNOR in hepatocytes of mice causes nitrosative inactivation of O6-alkylguanine-DNA alkyltransferase and increased sensitivity to genotoxic diethylnitrosamine.
Use of genetically manipulated Salmonella typhimurium strains to evaluate the role of human sulfotransferases in the bioactivation of nitro- and aminotoluenes.
Sepsis
Reduction of cardiomyocyte S-nitrosylation by S-nitrosoglutathione reductase protects against sepsis-induced myocardial depression.
Shock, Septic
A central role for S-nitrosothiols in plant disease resistance.
Reduction of cardiomyocyte S-nitrosylation by S-nitrosoglutathione reductase protects against sepsis-induced myocardial depression.
Tuberculosis
3D-QSAR and cell wall permeability of antitubercular nitroimidazoles against Mycobacterium tuberculosis.
A putative nitroreductase from the DosR regulon of Mycobacterium tuberculosis induces pro-inflammatory cytokine expression via TLR2 signaling pathway.
Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor.
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver.
Crystal structure of reduced MsAcg, a putative nitroreductase from Mycobacterium smegmatis and a close homologue of Mycobacterium tuberculosis Acg.
Hydrophobic Shielding Drives Catalysis of Hydride Transfer in a Family of F420H2-Dependent Enzymes.
Identification of a Mycobacterium tuberculosis putative classical nitroreductase gene whose expression is coregulated with that of the acr aene within macrophages, in standing versus shaking cultures, and under low oxygen conditions.
Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.
Mutations in Genes for the F420 Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in Spontaneous In Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis.
Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K.
Protonation state of F420H2 in the prodrug-activating deazaflavin dependent nitroreductase (Ddn) from Mycobacterium tuberculosis.
Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.
Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824.
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis.
Urinary Bladder Neoplasms
Enhancing effect of allopurinol on the induction of bladder cancer in rats by n-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide.